Merck, Bristol-Myers immunotherapies impress in key lung cancer trials – Reuters
Business Insider |
Merck, Bristol-Myers immunotherapies impress in key lung cancer trials
Reuters (Reuters) – Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to … 'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to … Merck lung cancer trial boosts immunotherapy hopes |
